Ambagon adds $85M for molecular glues that stick to elusive protein targets January 6, 2022 Auto Bot BioPharma, California, cancer, deals, Pharma, Protein Degradation, Startups 0 Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.